Ubie, a Japan-based AI-driven healthcare platform, announced on June 26, 2025, that it has raised over $125 million in cumulative funding since its founding in 2017. With recent investments from Google, JAPAN POST CAPITAL, NTT DOCOMO, SEVEN-ELEVEN JAPAN, Japan Finance Corporation, and The Shoko Chukin Bank, Ubie is accelerating its US expansion, focusing on generative AI and provider solutions.
Ubie’s total funding exceeds $125M, including a recent round with Google and others.
US Symptom Checker user base grows to 4 million, with 85% organic growth since 2024.
Accepted into Mayo Clinic’s Platform Accelerate to enhance provider solutions.
Generative AI to improve patient education and care navigation.
Serves 13 million monthly users globally, with 1,800+ medical institutions in Japan.
Partners with top pharmaceutical firms like Takeda, Pfizer, and Boehringer Ingelheim.
Ubie’s latest funding round, building on a $26.2M Series C in August 2022, brings its total capital to over $125M. Investors include global leaders like Google and Japan-based firms such as JAPAN POST CAPITAL and NTT DOCOMO. “Ubie has seen an increasing understanding and acknowledgment of the capabilities and impact we provide to patients, providers, and the healthcare system,” said Kota Kubo, Co-Founder and CEO. The funds will support US market expansion, focusing on enhancing its AI Symptom Checker and developing provider-facing solutions.
Ubie’s AI Symptom Checker, used by over 4 million US users with an 85% increase in monthly organic users since 2024, guides patients to appropriate care by analyzing symptoms with high accuracy. Validated against physician accuracy (72.9%), it has contributed to 27,000 quality-adjusted life years and $1 billion in economic value from 2021 to 2024. Partnerships with advocacy groups and life sciences companies like Takeda, Pfizer, and Boehringer Ingelheim enhance early disease detection and treatment.
Ubie is integrating generative AI to enhance patient education, delivering critical disease information and care guidance early in the patient journey. Its acceptance into the Mayo Clinic Platform Accelerate program allows Ubie to refine its platform using de-identified data from 3 million Mayo Clinic patients, improving accuracy for provider solutions like the Ubie Medical Navigator. This tool, adopted by over 1,800 medical institutions in Japan, streamlines patient intake and documentation with a 90% user satisfaction rate.
Globally, Ubie’s Symptom Checker serves over 13 million monthly users, while its Ubie for Pharma service collaborates with 21 of the top 30 global life sciences companies to provide disease and treatment awareness. In Japan, the Ubie Medical Navigator supports over 1,800 medical institutions, enhancing consultation quality. Strategic partnerships with Google’s Health Connect (Beta) and pharmaceutical giants underscore Ubie’s mission to bridge gaps in healthcare access.
Founded in 2017 by Yoshinori Abe, MD, and Kota Kubo, Ubie aims to create a society where everyone can access appropriate medical care. Its US subsidiary, established in 2022, drives global expansion. With Google’s backing and Mayo Clinic’s collaboration, Ubie is poised to transform healthcare through AI, focusing on patient empowerment and provider efficiency. “We’re proud to have accomplished so much in such a short time,” said Kubo, emphasizing Ubie’s role in addressing healthcare barriers.
Ubie’s $125M funding milestone and strategic partnerships position it as a leader in AI-driven healthcare, delivering impactful solutions for patients, providers, and pharmaceutical partners worldwide.
Founded in 2017, Ubie empowers individuals and healthcare professionals with the tools they need for better care. Leveraging cutting-edge disease prediction AI, Ubie guides 13+ million patients every month to seek appropriate medical attention through its free online Symptom Checker and equips 1,800+ provider organizations with clinical tools that streamline workflows and support better diagnoses and health outcomes. Trained on medical data, Ubie's marketing solutions power advanced targeting capabilities and high-performing digital campaigns for 21 out of top 30 world's top life science companies.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.